Basilea is one of the few standalone European companies focused on developing novel antimicrobial drugs. It has two approved hospital-based products: Cresemba for severe mold infections and Zevtera for bacterial infections. Together these underpin the current valuation with upside potential from a US partnering deal for Zevtera and the early-stage oncology pipeline. A US Zevtera deal and potential sales progression for the antimicrobial portfolio are key near-term share price drivers. We valu
23 Mar 2016
Riding the crest of the novel antimicrobial wave
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Riding the crest of the novel antimicrobial wave
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
23 Mar 2016 -
Author:
Dr Susie Jana -
Pages:
16
Basilea is one of the few standalone European companies focused on developing novel antimicrobial drugs. It has two approved hospital-based products: Cresemba for severe mold infections and Zevtera for bacterial infections. Together these underpin the current valuation with upside potential from a US partnering deal for Zevtera and the early-stage oncology pipeline. A US Zevtera deal and potential sales progression for the antimicrobial portfolio are key near-term share price drivers. We valu